Valproate and acetyl-L-carnitine prevent methamphetamine-induced behavioral sensitization in mice

Annals of the New York Academy of Sciences

Volumn 1122, Issue , 2007, Pages 260-275

  Coccurello, Roberto ^b   Caprioli, Antonio ^a   Ghirardi, Orlando ^a   Virmani, Ashraf ^a  

^a Sigma Tau SpA   (Italy)

^b CNR   (Italy)

Author keywords

Acetyl L carnitine; Behavioral sensitization; Dopamine supersensitivity; Drug addiction; Methamphetamine; Mitochondrial metabolism; Neuroprotection; Psychiatric disorders; Valproate

Indexed keywords

LEVACECARNINE; METHAMPHETAMINE; PSYCHOSTIMULANT AGENT; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; DRUG INHIBITION; DRUG MECHANISM; HYPERACTIVITY; HYPOTHESIS; IN VIVO STUDY; LOCOMOTION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PREVENTIVE MEDICINE; PSYCHOMOTOR ACTIVITY; SENSITIZATION;

MUS;

EID: 37049027671     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1403.019     Document Type: Conference Paper

References (70)

1. ROBINSON, T.E. & J.B. BECKER. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396: 157-198.
2. KALIVAS, P.W., B.A. SORG & M.S. HOOKS. 1993. The pharmacology and neural circuits of sensitization to psychostimulants. Behav. Pharmacol. 4: 315-334.
3. KALIVAS, P.W. & J. STEWART. 1991. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev. 16: 223-244.
4. SEGAL, D.S. & A.J. MANDELL. 1974. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol. Biochem. Behav. 2: 249-255.
5. PIERCE, R.C. & P.W. KALIVAS. 1997. A circuitry model of the expression of behavioural sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev. 25: 192-216.
6. HEIKKILA, R.E., H. ORLANSKY & G. COHEN. 1975. Studies on the distinction between uptake inhibition and release of 3 H-dopamine in rat brain tissue slices. Biochem. Pharmacol. 24: 847-852.
7. SEIDEN, L.S., K.E. SABOL & G.A. RICAURTE. 1993. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 32: 639-677.
8. JONES, S.R., J.D. JOESPH, L.S. BARAK, M.G. CARON, et al. 1999. Dopamine neural transport kinetics and effects of amphetamine. J. Neurochem. 73: 2406-2414.
9. TZSCHENTKE, T.M. & W.J. SCHMIDT. 2003. Glutamatergic mechanisms in addiction. Mol. Psychiatry 8: 373-382.
10. SCHEEL-KRUGER, J. 1986. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol. Scand. Suppl. 107: 1-54.
11. SCATTON, B., B. ZIVKOVIC, J. DEDEK, et al. 1982. Gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J. Pharmacol. Exp. Ther. 220: 678-688.
12. COTT, J. & J. ENGEL. 1977. Suppression by GABAergic drugs of the locomotor stimulation induced by morphine, amphetamine, and apomorphine: evidence for both pre- and post-synaptic inhibition of catecholamine systems. J. Neural. Transm. 40: 253-268.
13. WOO, S.H., H.S. KIM, J.S. YUN, et al. 2001. Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity. Pharmacol. Res. 43: 335-340.
14. RANALDI, R. & K. POEGGEL. 2002. Baclofen decreases methamphetamine self-administration in rats. Neuroreport 13: 1107-110.
15. ITZHAK, Y. & J.L. MARTIN. 2000. Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice. Psychopharmacology 151: 226-233.
16. LI, J.X., R. HAN & Y.P. DENG, et al. 2005. Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behav. Brain Res. 161: 125-132.
17. LI, J.X., Q. ZHANG & J.H. LIANG. 2004. Valproate prevents the induction, but not the expression of morphine sensitization in mice. Behav. Brain Res. 152: 251-257.
18. BAHL, I.J. & R. BRESSLER. 1987. The pharmacology of carnitine. Annu. Rev. Pharmacol. Toxicol. 27: 257-277.
19. BEAL, M.F. 2003. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53: S39-S47.
20. VIRMANI, M.A., R. BISELLI, A. SPADONI, et al. 1995. Protective actions of l-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res. 32: 383-389.
21. BINIENDA, Z.K. & S.F. ALI. 2001. Neuroprotective role of l-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicol. Lett. 125: 67-73.
22. BINIENDA, Z.K., J.R. JOHNSON, A.A. TYLER- HASHEMI, et al. 1999. Protective effect of l-carnitine in the neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA). Ann. N. Y. Acad. Sci. 890: 173-178.
23. VIRMANI, A., F. GAETANI, Z. BINIENDA, et al. 2004. Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine. Ann. N. Y. Acad. Sci. 1025: 267-273.
24. BODIS-WOLLNER, I., E. CHUNG, M.F. GHILARDI, et al. 1991. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neural Transm. Park. Dis. Dementia Sect. 3: 63-72.
25. MAZZIO, E., K.J. YOON & K.F. SOLIMAN. 2003. Acetyl-L-carnitine cytoprotection against 1-methyl-4- phenylpyridinium toxicity in neuroblastoma cells. Biochem. Pharmacol. 66: 297-306.
26. VIRMANI, A., F. GAETANI, S. IMAM, et al. 2002. The protective role of l-Carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann. N. Y. Acad. Sci. 965: 225-232.
27. HASHIMOTO, K., H. TSUKADA, S. NISHIYAMA, et al. 2004. Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 29: 2018-2023.
28. SANDOVAL, V. G.R. HANSON & A.E. FLECKENSTEIN. 2000. Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine. Eur. J. Pharmacol. 409: 265-271.
29. WILSON, J.M., K.S. KALASINSKY, A.I. LEVEY, et al. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2: 699-703.
30. FLECKENSTEIN, A.E., R.R. METZGER, D.G. WILKINS, et al. 1997. Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 282: 834-838.
31. METZGER, R.R., H.M. HAUGHEY, D.G. WILKINS, et al. 2000. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J. Pharmacol. Exp. Ther. 295: 1077-1085.
32. ZHANG, L., K. KITAICHI, Y. FUJIMOTO, et al. 2006. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 30: 1381-1393.
33. FUKAMI, G., K. HASHIMOTO, K. KOIKE, et al. 2004. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 1016: 90-95.
34. ITZHAK, Y., J.L. MARTIN, M.D. BLACK, et al. 1998. Effect of melatonin on methamphetamine- and 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neuropharmacology 37: 781-791.
35. CHIU, C.T., T. MA & I.K. HO. 2005. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res. Bull. 67: 100-109.
36. HIRABAYASHI, M. & M.R. ALAM. 1981. Enhancing effect of methamphetamine on ambulatory activity produced by repeated administration in mice. Pharmacol. Biochem. Behav. 15: 925-932.
37. KURIBARA, H. 1996. Effects of interdose interval on ambulatory sensitization to methamphetamine, cocaine and morphine in mice. Eur. J. Pharmacol. 316: 1-5.
38. PIOVESAN, P., L. PACIFICI, G. TAGLIALATELA, et al. 1994. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 633: 77-82.
39. SCARFO, C., M. FALCINELLI, L. PACIFICI, et al. 1992. Morphological and electrophysiological changes of peripheral nerve-muscle unit in the aged rat prevented by levocarnitine acetyl. Int. J. Clin. Pharmacol. Res. 12: 253-262.
40. LÖSCHER, W. 1999. Valproate: a reappraisal of its pharmacodynamic properties and mechanism of action. Prog. Neurobiol. 58: 31-59.
41. REBOUCHE, C.J. 2004. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-L-carnitine metabolism. Ann. N. Y. Acad. Sci. 1033: 30-41.
42. KIDO, Y., I. TAMAI, A. OHNARI, et al. 2001. Functional relevance of carnitine transporter OCTN2 to brain distribution of l-carnitine and acetyl-L-carnitine across the blood-brain barrier. J. Neurochem. 79: 959-969.
43. INANO, A., Y. SAI, H. NIKAIDO, et al. 2003. Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm. Drug Dispos. 24: 357-365.
44. AGMO, A., C. BELZUNG & M. GIORDANO. 1996. Interaction between dopamine and GABA in the control of ambulatory activity. J. Neural. Transm. 103: 925-934.
45. COTT, J. & J. ENGEL. 1977. Suppression by GABA-ergic drugs of the locomotor stimulation induced by morphine, amphetamine and apomorphine: evidence for both pre- and post-synaptic inhibition of catecholamine systems. J. Neural. Transm. 40: 253-268.
46. YANG, P.B., A.C. SWANN & N. DAFNY. 2002. Valproate prevents the induction and the expression of MK-801 sensitization. Brain Res. 954: 151-159.
47. NESTLER, E.J. & G.K. AGHAJANIAN. 1997. Molecular and cellular basis of addiction. Science 278: 58-63.
48. KALIVAS, P.W. & N.D. VOLKOW. 2005. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 162: 1403-1413.
49. BIBB, J.A., J.S. CHEN, J.R. TAYLOR, et al. 2001. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 410: 376-380.
50. NARITA, M., M. SHIBASAKI, Y. NAGUMO, et al. 2005. Implication of cyclin-dependent kinase 5 in the development of psychological dependence on and behavioral sensitization to morphine. J. Neurochem 93: 1463-1468.
51. NISHI, A., J.A. BIBB, G. SNYDER, et al. 2000. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci.USA97: 12840-12845.
52. CHEN, P.C. & J.C. CHEN. 2005. Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats. Neuropsychopharmacology 30: 538-549.
53. WALAAS, S.I., D.W. ASWAD & P. GREENGARD. 1983. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301: 68-71.
54. SCHEGGI, S., R. RAUGGI, G. NANNI, et al. 2004. Repeated acetyl-L-carnitine administration increases phospho-Thr34 DARPP-32 levels and antagonizes cocaine-induced increase in Cdk5 and phospho-Thr75 DARPP-32 levels in rat striatum. Eur. J. Neurosci. 19: 1609-1620.
55. NASH, J.F. & B.K. YAMAMOTO. 1992. METH neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxy- METH. Brain Res. 581: 237-243.
56. STEPHANS, S.E. & B.K. YAMAMOTO. 1994. METH-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17: 203-209.
57. BECKMAN, J.S., T.W. BECKMAN, J. CHEN, et al. 1990. Apparent hydroxyl radical production by peroxynitrite; implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87: 1621-1624.
58. ITZHAK, Y. & S.F. ALI. 1996. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protect against methamphetamine- induced neurotoxicity in vivo. J. Neurochem. 67: 1770-1773.
59. ITZHAK, Y., C. GANDIA, P.L. HUANG, et al. 1998. Resistance to neuronal nitric oxide synthase deficient mice to methamphetamine-induced dopaminergic neurotoxicity in vivo. J. Pharmacol. Exp. Ther. 284: 1040-1047.
60. CALABRESE, V., G. SCAPAGNINI, A. RAVAGNA, et al. 2003. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem. Res. 28: 1321-1328.
61. BROWN, J.M. & B.K. YAMAMOTO. 2005. Effects of amphetamine on mitochondrial function: role of free radicals and oxidative stress. Pharmacol. Ther. 99: 45-53.
62. BROWN, J.M., M.S. QUINTON & B.K. YAMAMOTO. 2005. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J. Neurochem. 95: 429-436.
63. FORLONI, G., N. ANGERETTI & S. SMIROLDO. 1994. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. J. Neurosci. Res. 37: 92-96.
64. FARIELLO, R.G., T.N. FERRARO, G.T. GOLDEN, et al. 1988. Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA. Life Sci. 43: 289-292.
65. VIRMANI, M.A., R. CONTI, A. SPADONI, et al. 1995. Inhibition of L-carnitine uptake into primary rat cortical cell cultures by GABA and GABA uptake blockers. Pharmacol. Res. 31: 211-215.
66. ECKERMANN, K., A. BEASLEY, P. YANG, et al. 2001. Methylphenidate sensitization is modulated by valproate. Life Sci. 69: 47-57.
67. KRISHNAN, K.R. 2005. Psychiatric and medical comorbidities of bipolar disorder. Psychosom. Med. 67: 1-8.
68. ADRIANI, W., M. REA, M. BAVIERA, et al. 2004. Acetyl-l-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology 176: 296-304.
69. BRADY, K.T. & S.C. SONNE. 1995. The relationship between substance abuse and bipolar disorder. J. Clin. Psychiatry 56: 19-24.
70. REGIER, D.A., M.E. FARMER, D.S. RAE, et al. 1990. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511-2518.